Press Releases

EcoCerta Biotecnologia Licenses Genetic ID’s GMO Testing Technology Genetic ID

testing technology to EcoCerta Analises Ambientais Ltda. (EcoCerta) in Brazil. As a licensee, EcoCerta will add GMO and species testing of agricultural and food products to its environmental testing portfolio. EcoCerta joins Genetic ID’s global network of GMO...

Polyplus-transfection announces the appointment of ten additional biologists and chemists to support multiple pre-clinical studies

Strasbourg, France, September 15, 2011 - Polyplus-transfection SA, which specializes in the development of innovative solutions for the delivery of nucleic acids in research and therapeutics, today celebrates ten years of continuous growth. From its...

Less Than Half of Cancer Patients Informed of Fertility Preservation Options

Kim Kincaid had just met with her doctor to start planning a family when she received devastating news that same week — the 37-year-old East Bay executive had breast cancer. In California, more women are diagnosed with breast...

Pfizer Extends Subsequent Offering Period of Tender Offer to Acquire Icagen, Inc.

Pfizer Inc. and Icagen, Inc. announced today that Pfizer’s wholly-owned subsidiary, Eclipse Acquisition Corp., has extended the expiration date of the subsequent offering period of its tender offer for all outstanding shares of common stock of Icagen for...

Mayo Clinic Teams with Glowing Cats Against AIDS, Other Diseases

Mayo Clinic researchers have developed a genome-based immunization strategy to fight feline AIDS and illuminate ways to combat human HIV/AIDS and other diseases. The goal is to create cats with intrinsic immunity to the feline AIDS virus. The...

Exelixis Announces Webcasts of Upcoming Investor Conference Presentations Exelixis Inc.

Exelixis, Inc. announced today that Michael Morrissey, PhD, the company’s president and chief executive officer, will present at two upcoming investor conferences.  Morgan Stanley Global Healthcare Conference: Exelixis’ presentation will take place at 10:20...

Sucampo and Numab Sign Drug Discovery Collaboration Sucampo Pharmaceuticals Inc. and Numab AG

Sucampo Pharmaceuticals, Inc. an international pharmaceutical company, and Numab AG today announced that Sucampo’s wholly owned subsidiary, Sucampo AG, and Numab AG, have entered into a research and development collaboration that provides Sucampo with access to Numab’s proprietary...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read